TC
TBRA

TradeLink Capital’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

TradeLink Capital’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-111
Closed -$13K – 419
2014
Q1 		$13K Buy
+111
New +$7.79K 0.02% 220

Other funds holding TBRA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIA
Biondo Investment Advisors Milford, Pennsylvania $780M AUM 21.03% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return

TradeLink Capital's TBRA Position: Q2 2014 in Review

TradeLink Capital sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2014, closing a stake of 111 shares — an estimated $13K sold.

TradeLink Capital first reported a position in TBRA in Q1 2014 and held it in 1 quarter. The position peaked at $13K in Q1 2014. 49 funds tracked by Wall St. Rank hold TBRA as of Q2 2014.

  • TradeLink Capital reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • TradeLink Capital sold 111 Tobira Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $13K.
  • TradeLink Capital first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • TradeLink Capital's Tobira Therapeutics, Inc. Common Stock position peaked at $13K in Q1 2014.
  • 49 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2014.

Based on TradeLink Capital's 13F filing for Q2 2014, filed 31 Jul 2014.